CD34+hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, sa.8, ss.1851-1856, 2020 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 8
- Basım Tarihi: 2020
- Doi Numarası: 10.3906/sag-2001-173
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.1851-1856
- Anahtar Kelimeler: Multiple myeloma, CD34(+) hematopoietic progenitor cell, engraftment, survival, BLOOD, MOBILIZATION, GUIDELINES, MANAGEMENT, COLLECTION, DIAGNOSIS, LYMPHOMA
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34(+) hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 x 10(6)/kg. The aim of this study was to evaluate the relationship between the dose of CD3V4(+). HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.